Welcome to our dedicated page for Forrester Resh SEC filings (Ticker: FORR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind Forrester’s subscription renewals or curious when executives last sold shares? Our SEC filings hub answers those questions in minutes, not hours. Investors often search for “Forrester Research insider trading Form 4 transactions” or “Forrester Research quarterly earnings report 10-Q filing”. We bring every disclosure together and layer it with AI so you see the story behind the figures.
Skip the 200-page PDFs. Stock Titan’s platform delivers:
- AI-powered summaries that turn dense footnotes into plain language—ideal for understanding Forrester Research SEC documents with AI
- Real-time alerts for Forrester Research Form 4 insider transactions real-time and 8-K headlines
- Side-by-side trend charts so you can compare research, consulting, and event revenue across quarters
The annual report—searchable as “Forrester Research annual report 10-K simplified”—breaks down deferred revenue and contract liabilities. The 10-Q provides margin updates you’ll need for a quick “Forrester Research earnings report filing analysis”. Material announcements, like leadership changes, appear in “Forrester Research 8-K material events explained”. If executive pay matters to you, the proxy—often Googled as “Forrester Research proxy statement executive compensation”—is parsed so you can scan option grants in seconds.
From Forrester Research executive stock transactions Form 4 to forward-looking risk factors, every filing is indexed and updated the moment it hits EDGAR. Use our export tools to monitor renewal ratios, track insider sentiment, and understand how event seasonality shapes cash flow—all without wading through legal jargon. Complex disclosures, clarified.
Omeros Corporation (OMER) filed a Form 4 disclosing that non-employee director Dr. Leroy E. Hood received an annual stock-option grant for 15,000 shares on 27 Jun 2025. The option carries a $3.20 exercise price, a 10-year term expiring 27 Jun 2035, and will vest in full the day before the 2026 annual shareholder meeting provided he remains a director. No open-market purchases or sales of common stock were reported, and Table I shows no change in non-derivative share ownership. The filing reflects routine director compensation and represents a negligible portion of Omeros’ total shares outstanding, implying minimal immediate dilution or market impact.